Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 18/20 | 0.77 |
| ▸ | DHODH | Q02127 | 2/20 | 0.72 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.70 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.68 |
| ▸ | PLK4 | O00444 | 1/20 | 0.68 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.68 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.68 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.68 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.68 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.68 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.68 |
| ▸ | PIM1 | P11309 | 1/20 | 0.68 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.68 |
| ▸ | PRKACA | P17612 | 1/20 | 0.68 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.68 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.68 |
| ▸ | CLK2 | P49760 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31027911 | 1.00 | PARP1 (0.77) | PARP1DHODHPLA2G2AALOX15PTGS2 | |
| SCHEMBL21705588 | 0.88 | DHODH (0.73) | PARP1DHODH | |
| SCHEMBL31027888 | 0.88 | DHODH (0.73) | PARP1DHODH | |
| SCHEMBL7318483 | 0.87 | PARP1 (1.00) | PARP1DHODHPLA2G2AALOX15PTGS2 | |
| SCHEMBL18252746 | 0.85 | PARP1 (0.78) | PARP1DHODHPLA2G2AALOX15PTGS2 | |
| SCHEMBL2298622 | 0.84 | PARP1 (0.69) | PARP1DHODHPLA2G2AALOX15PTGS2 | |
| SCHEMBL7316597 | 0.84 | PARP1 (1.00) | PARP1DHODHPLA2G2AALOX15PTGS2 | |
| SCHEMBL29380664 | 0.84 | PARP1 (1.00) | PARP1DHODHPLA2G2AALOX15PTGS2 | |
| SCHEMBL505358 | 0.84 | PARP1 (1.00) | PARP1DHODHPLA2G2AALOX15PTGS2 | |
| SCHEMBL423551 | 0.84 | PARP1 (1.00) | PARP1DHODHPLA2G2AALOX15PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-30 | — | — | US | disclosed |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-03-04 | — | — | US | disclosed |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020033359-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | PARP1 2130/4885DHODH 4319/4885PLA2G2A 1465/4885 |
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | PARP1 2280/4885DHODH 4467/4885PLA2G2A 908/4885 |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | PARP1 2078/4885DHODH 4301/4885PLA2G2A 1505/4885 |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | PARP1 2078/4885DHODH 4301/4885PLA2G2A 1505/4885 |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | PARP1 2130/4885DHODH 4319/4885PLA2G2A 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.